These findings provide valuable insights for clinical translation, with the combination of ACSL3 knockdown and anti-PD-1 therapy potentially preventing lung adenocarcinoma progression by increasing interferon-α (IFN-α) secretion, enhancing CD8+ T-cell infiltration and reducing immunosuppressive M2-like macrophages [109]. Here, ACSL3 is linked to lung adenocarcinoma.